PMID- 27034533
OWN - NLM
STAT- MEDLINE
DCOM- 20161028
LR  - 20181113
IS  - 1875-8630 (Electronic)
IS  - 0278-0240 (Print)
IS  - 0278-0240 (Linking)
VI  - 2016
DP  - 2016
TI  - HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial 
      Carcinoma of the Urinary Bladder.
PG  - 8463731
LID - 10.1155/2016/8463731 [doi]
LID - 8463731
AB  - AIM: HER2 overexpression has been reported in a minority of urothelial 
      carcinomas, but little is known about HER2 protein expression and gene 
      alterations in plasmacytoid urothelial carcinoma, a rare and aggressive variant. 
      The aim of this study was to clarify the HER2 status in plasmacytoid urothelial 
      carcinomas. METHODS: Six cases of plasmacytoid urothelial carcinoma were 
      included, in which we evaluated HER2 protein expression by immunohistochemistry 
      (IHC) and HER2 gene amplification by fluorescence in situ hybridization (FISH). 
      RESULTS: The patients' ages ranged from 57 to 83 years (mean age, 71 years). Five 
      patients were male and one was female. The ratio of the plasmacytoid component 
      ranged from 30% to 100% (mean, 77%). HER2 expression score was 3+ in 4 cases, 2+ 
      in one case, and negative in one case. HER2 gene amplification was positive in 3 
      cases, of which 2 cases showed a 3+ HER2 IHC score but one case was negative for 
      HER2 IHC. Another 2 cases showed equivocal HER2 FISH results, and one remaining 
      case was negative for HER2 FISH. CONCLUSION: Our observation that plasmacytoid 
      urothelial carcinomas frequently demonstrated HER2 protein overexpression 
      provides supporting evidence that HER2 may be a potential therapeutic target for 
      plasmacytoid urothelial carcinoma.
FAU - Kim, Bohyun
AU  - Kim B
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      03080, Republic of Korea.
FAU - Kim, Gilhyang
AU  - Kim G
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      03080, Republic of Korea.
FAU - Song, Boram
AU  - Song B
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      03080, Republic of Korea.
FAU - Lee, Cheol
AU  - Lee C
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      03080, Republic of Korea.
FAU - Park, Jeong Hwan
AU  - Park JH
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      03080, Republic of Korea.
FAU - Moon, Kyung Chul
AU  - Moon KC
AUID- ORCID: 0000-0002-1969-8360
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      03080, Republic of Korea; Kidney Research Institute, Medical Research Center, 
      Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160310
PL  - United States
TA  - Dis Markers
JT  - Disease markers
JID - 8604127
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Transitional Cell/genetics/*metabolism/pathology
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - *Up-Regulation
MH  - Urinary Bladder Neoplasms/genetics/*metabolism/pathology
PMC - PMC4806278
EDAT- 2016/04/02 06:00
MHDA- 2016/11/01 06:00
PMCR- 2016/03/10
CRDT- 2016/04/02 06:00
PHST- 2015/12/02 00:00 [received]
PHST- 2016/02/18 00:00 [accepted]
PHST- 2016/04/02 06:00 [entrez]
PHST- 2016/04/02 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
PHST- 2016/03/10 00:00 [pmc-release]
AID - 10.1155/2016/8463731 [doi]
PST - ppublish
SO  - Dis Markers. 2016;2016:8463731. doi: 10.1155/2016/8463731. Epub 2016 Mar 10.